|1.||Sandborn, William J: 21 articles (11/2014 - 01/2002)|
|2.||Sandborn, W J: 15 articles (11/2015 - 07/2000)|
|3.||Moss, Alan C: 12 articles (11/2015 - 05/2006)|
|4.||Gasche, Christoph: 11 articles (12/2015 - 05/2005)|
|5.||Lichtenstein, G R: 11 articles (07/2012 - 10/2000)|
|6.||Hanauer, Stephen B: 11 articles (05/2012 - 12/2003)|
|7.||Munkholm, Pia: 10 articles (08/2015 - 09/2002)|
|8.||Tursi, Antonio: 10 articles (01/2015 - 01/2004)|
|9.||Lichtenstein, Gary R: 10 articles (08/2014 - 01/2007)|
|10.||Pallone, Francesco: 10 articles (09/2013 - 10/2006)|
02/01/2011 - "Mesalazine 3.0 g once daily was the most effective dose for maintenance of remission in ulcerative colitis of the three regimens assessed, with no penalty in terms of safety."
08/01/2010 - "Best practice in the management of mild-to-moderately active ulcerative colitis and achieving maintenance of remission using mesalazine."
09/21/2009 - "5-Aminosalicylic acid (5-ASA) compounds are a highly effective treatment for ulcerative colitis (UC). "
01/01/2006 - "The new oral mesalamine formulation is a once-daily MMX tablet that delivers the mesalamine to the colon, making it most useful in the treatment of ulcerative colitis. "
05/01/1991 - "Topical mesalazine has proved extremely effective in patients with distal ulcerative colitis; oral forms are effective in the treatment of mild to moderately active ulcerative colitis and in relapse. "
|2.||Crohn Disease (Crohn's Disease)
10/01/1997 - "Recent data indicate that 5-aminosalicylic acid (5-ASA) is most effective in preventing relapse of Crohn's disease in patients with a short duration of remission before enrollment. "
03/01/1996 - "The aim of this study was to test the efficacy of a 12-week oral intake of Claversal in the prevention of endoscopic recurrences after 'curative' resection for ileal, colonic or ileocolonic Crohn's disease. "
04/01/1995 - "Included were 59 patients who had proven Crohn's disease of at least 1 year's duration, and who had been in continuous remission for at least 6 months, while taking only 5-aminosalicylic acid or no therapy at all. "
05/23/1998 - "The efficacy of mesalazine in active Crohn's disease is limited and high doses are required (4000 mg/day). "
05/01/1995 - "Although the major part of continuous-release mesalamine is delivered to the colon, large proportions are liberated and available at high concentrations within the small intestinal lumen, thus explaining its therapeutic efficacy in small intestinal Crohn's disease."
05/01/2005 - "The colitis score improved similarly in both patient groups (by 2.3 with Ipocol and by 1.5 with Asacol: not significant), and a similar proportion was in clinical remission at the end of the study (26.1% for Ipocol and 28.6% for Asacol: not significant). "
09/01/1999 - "These studies show that an NO-releasing derivative of mesalamine has significantly enhanced anti-inflammatory activity, including improved efficacy in a rat model of colitis. "
07/28/2015 - "Furthermore, we confirmed a significant reduction of disease activity and a robust dose response efficacy following RNP(O) treatment in acute DSS-induced colitis mice, outperforming the positive control 5-aminosalicylic acid. "
11/01/2014 - "We screened 119 patients with UC in remission on the basis of Simple Clinical Colitis Activity Index scores, FC >50 μg/g, and intake of no more than 3 g/day mesalamine. "
04/01/2007 - "Mesalamine is the first-line therapy for colitis, but it lacks potency and is only effective for mild-to-moderate forms of this disease. "
|4.||Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
10/01/1994 - "These studies strongly suggest that mesalazine microgranules are effective for idiopathic inflammatory bowel disease."
10/01/2014 - "Mesalamine has shown efficacy in preventing relapse in inflammatory bowel disease, and there is preliminary evidence that it might be effective for diverticular disease. "
04/01/2013 - "5-aminosalicylic acid (5-ASA) is widely used for the treatment of inflammatory bowel disease (IBD). "
10/01/2012 - "Mesalamine is an anti-inflammatory agent, effective in the treatment of inflammatory bowel disease. "
05/18/2009 - "Mesalamine is a locally acting antiinflammatory agent that is widely used both to maintain and induce remission in inflammatory bowel disease. "
05/01/2012 - "However, because most studies included only patients with left-sided disease or proctitis, the efficacy of topical mesalamine in preventing relapse in patients with more extensive quiescent UC is not known."
11/01/2010 - "In active ulcerative proctitis the once-daily administration of a 1 g mesalamine suppository is as effective and safe, yet considerably more convenient, than the standard thrice-daily administration of a 0.5 g mesalamine suppository."
01/01/1992 - "Therapeutic efficacy of mesalazine controlled-release suppository 1 g once daily was compared with that of a placebo during 2 weeks in 50 patients (26 in the mesalazine group, 24 in the placebo group) with ulcerative proctitis, in a double-blind randomized trial. "
02/01/1998 - "Daily administration of rectal formulations of mesalazine is effective in preventing relapse of ulcerative proctitis. "
01/01/1992 - "It is concluded that a once-a-day administration of 1 g mesalazine controlled-release suppository is effective for topical treatment of patients with ulcerative proctitis."
|6.||Suppositories (Vaginal Suppositories)
|7.||Adrenal Cortex Hormones (Corticosteroids)